460 related articles for article (PubMed ID: 29120012)
1. Hepatitis C virus dynamics among intravenous drug users suggest that an annual treatment uptake above 10% would eliminate the disease by 2030.
Bruggmann P; Blach S; Deltenre P; Fehr J; Kouyos R; Lavanchy D; Müllhaupt B; Rauch A; Razavi H; Schmid P; Semela D; Stoeckle M; Negro F
Swiss Med Wkly; 2017; 147():w14543. PubMed ID: 29120012
[TBL] [Abstract][Full Text] [Related]
2. Treatment and primary prevention in people who inject drugs for chronic hepatitis C infection: is elimination possible in a high-prevalence setting?
Gountas I; Sypsa V; Anagnostou O; Martin N; Vickerman P; Kafetzopoulos E; Hatzakis A
Addiction; 2017 Jul; 112(7):1290-1299. PubMed ID: 28107585
[TBL] [Abstract][Full Text] [Related]
3. Mitigating the burden of hepatitis C virus among people who inject drugs in Belgium.
Matheï C; Bourgeois S; Blach S; Brixko C; Mulkay JP; Razavi H; Robaeys G
Acta Gastroenterol Belg; 2016; 79(2):227-32. PubMed ID: 27382943
[TBL] [Abstract][Full Text] [Related]
4. Evaluating the population impact of hepatitis C direct acting antiviral treatment as prevention for people who inject drugs (EPIToPe) - a natural experiment (protocol).
Hickman M; Dillon JF; Elliott L; De Angelis D; Vickerman P; Foster G; Donnan P; Eriksen A; Flowers P; Goldberg D; Hollingworth W; Ijaz S; Liddell D; Mandal S; Martin N; Beer LJZ; Drysdale K; Fraser H; Glass R; Graham L; Gunson RN; Hamilton E; Harris H; Harris M; Harris R; Heinsbroek E; Hope V; Horwood J; Inglis SK; Innes H; Lane A; Meadows J; McAuley A; Metcalfe C; Migchelsen S; Murray A; Myring G; Palmateer NE; Presanis A; Radley A; Ramsay M; Samartsidis P; Simmons R; Sinka K; Vojt G; Ward Z; Whiteley D; Yeung A; Hutchinson SJ
BMJ Open; 2019 Sep; 9(9):e029538. PubMed ID: 31551376
[TBL] [Abstract][Full Text] [Related]
5. Mathematical Modeling of Hepatitis C Prevalence Reduction with Antiviral Treatment Scale-Up in Persons Who Inject Drugs in Metropolitan Chicago.
Echevarria D; Gutfraind A; Boodram B; Major M; Del Valle S; Cotler SJ; Dahari H
PLoS One; 2015; 10(8):e0135901. PubMed ID: 26295805
[TBL] [Abstract][Full Text] [Related]
6. Scaling up prevention and treatment towards the elimination of hepatitis C: a global mathematical model.
Heffernan A; Cooke GS; Nayagam S; Thursz M; Hallett TB
Lancet; 2019 Mar; 393(10178):1319-1329. PubMed ID: 30704789
[TBL] [Abstract][Full Text] [Related]
7. Association between rapid utilisation of direct hepatitis C antivirals and decline in the prevalence of viremia among people who inject drugs in Australia.
Iversen J; Dore GJ; Catlett B; Cunningham P; Grebely J; Maher L
J Hepatol; 2019 Jan; 70(1):33-39. PubMed ID: 30367897
[TBL] [Abstract][Full Text] [Related]
8. The Potential Impact of a Hepatitis C Vaccine for People Who Inject Drugs: Is a Vaccine Needed in the Age of Direct-Acting Antivirals?
Stone J; Martin NK; Hickman M; Hellard M; Scott N; McBryde E; Drummer H; Vickerman P
PLoS One; 2016; 11(5):e0156213. PubMed ID: 27224423
[TBL] [Abstract][Full Text] [Related]
9. Planning the hepatitis C virus elimination in Cyprus: A modeling study.
Gountas I; Yiasemi I; Kyprianou E; Mina C; Georgiou C; Katsioloudes P; Kouroufexi A; Demetriou A; Xenofontos E; Nikolopoulos G
World J Gastroenterol; 2021 Aug; 27(31):5219-5231. PubMed ID: 34497446
[TBL] [Abstract][Full Text] [Related]
10. Effectiveness and cost-effectiveness of interventions targeting harm reduction and chronic hepatitis C cascade of care in people who inject drugs: The case of France.
Cousien A; Tran VC; Deuffic-Burban S; Jauffret-Roustide M; Mabileau G; Dhersin JS; Yazdanpanah Y
J Viral Hepat; 2018 Oct; 25(10):1197-1207. PubMed ID: 29660211
[TBL] [Abstract][Full Text] [Related]
11. Population-level estimates of hepatitis C reinfection post scale-up of direct-acting antivirals among people who inject drugs.
Yeung A; Palmateer NE; Dillon JF; McDonald SA; Smith S; Barclay S; Hayes PC; Gunson RN; Templeton K; Goldberg DJ; Hickman M; Hutchinson SJ
J Hepatol; 2022 Mar; 76(3):549-557. PubMed ID: 34634387
[TBL] [Abstract][Full Text] [Related]
12. Modelling the elimination of hepatitis C as a public health threat in Iceland: A goal attainable by 2020.
Scott N; Ólafsson S; Gottfreðsson M; Tyrfingsson T; Rúnarsdóttir V; Hansdottir I; Hernandez UB; Sigmundsdóttir G; Hellard M
J Hepatol; 2018 May; 68(5):932-939. PubMed ID: 29274408
[TBL] [Abstract][Full Text] [Related]
13. Assessing the Long-Term Impact of Treating Hepatitis C Virus (HCV)-Infected People Who Inject Drugs in the UK and the Relationship between Treatment Uptake and Efficacy on Future Infections.
Bennett H; McEwan P; Sugrue D; Kalsekar A; Yuan Y
PLoS One; 2015; 10(5):e0125846. PubMed ID: 25938458
[TBL] [Abstract][Full Text] [Related]
14. Are Interferon-Free Direct-Acting Antivirals for the Treatment of HCV Enough to Control the Epidemic among People Who Inject Drugs?
Lima VD; Rozada I; Grebely J; Hull M; Lourenco L; Nosyk B; Krajden M; Yoshida E; Wood E; Montaner JS
PLoS One; 2015; 10(12):e0143836. PubMed ID: 26633652
[TBL] [Abstract][Full Text] [Related]
15. Modeling Hepatitis C Elimination Among People Who Inject Drugs in New Hampshire.
Blake A; Smith JE
JAMA Netw Open; 2021 Aug; 4(8):e2119092. PubMed ID: 34342652
[TBL] [Abstract][Full Text] [Related]
16. Gaps in hepatitis C virus prevention and care for HIV-hepatitis C virus co-infected people who inject drugs in Canada.
Lanièce Delaunay C; Maheu-Giroux M; Marathe G; Saeed S; Martel-Laferrière V; Cooper CL; Walmsley S; Cox J; Wong A; Klein MB;
Int J Drug Policy; 2022 May; 103():103627. PubMed ID: 35218989
[TBL] [Abstract][Full Text] [Related]
17. Prevalence of hepatitis C and pre-testing awareness of hepatitis C status in 1500 consecutive PWID participants at the Stockholm needle exchange program.
Kåberg M; Hammarberg A; Lidman C; Weiland O
Infect Dis (Lond); 2017 Oct; 49(10):728-736. PubMed ID: 28574295
[TBL] [Abstract][Full Text] [Related]
18. Is hepatitis C virus (HCV) elimination achievable among people who inject drugs in Tijuana, Mexico? A modeling analysis.
Marquez LK; Cepeda JA; Bórquez A; Strathdee SA; Gonzalez-Zúñiga PE; Fleiz C; Rafful C; Garfein RS; Kiene SM; Brodine S; Martin NK
Int J Drug Policy; 2021 Feb; 88():102710. PubMed ID: 32165050
[TBL] [Abstract][Full Text] [Related]
19. Reduction in the population prevalence of hepatitis C virus viraemia among people who inject drugs associated with scale-up of direct-acting anti-viral therapy in community drug services: real-world data.
Palmateer NE; McAuley A; Dillon JF; McDonald S; Yeung A; Smith S; Barclay S; Hayes P; Shepherd SJ; Gunson RN; Goldberg DJ; Hickman M; Hutchinson SJ
Addiction; 2021 Oct; 116(10):2893-2907. PubMed ID: 33651446
[TBL] [Abstract][Full Text] [Related]
20. Model projections on the impact of HCV treatment in the prevention of HCV transmission among people who inject drugs in Europe.
Fraser H; Martin NK; Brummer-Korvenkontio H; Carrieri P; Dalgard O; Dillon J; Goldberg D; Hutchinson S; Jauffret-Roustide M; Kåberg M; Matser AA; Matičič M; Midgard H; Mravcik V; Øvrehus A; Prins M; Reimer J; Robaeys G; Schulte B; van Santen DK; Zimmermann R; Vickerman P; Hickman M
J Hepatol; 2018 Mar; 68(3):402-411. PubMed ID: 29080808
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
